Banner for leaf pages 2

Saxagliptin (Onglyza)

Also known as Kombiglyze 2.5/1000, Kombiglyze 5/1000, Kombiglyze 5/500, and Onglyza

Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. It was based on a drug development program with 8 randomized trials: 1 phase 2 dose-ranging (2.5–100 mg/d) study; 6 phase 3, 24-week controlled trials with additional controlled follow-up from 12 to 42 months, double-blinded throughout; and one 12-week mechanism-of-action trial with a 2-year follow-up period. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed.

Source: Wikipedia

Estimated Total Cost: $176.24 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed saxagliptin to treat diabetes, rabies, blastomycosis, and west nile virus.

Ajax-loader Loading...